Baidu
map

Breast Cancer Res:蛋白Perp与细胞桥粒或成抑制乳腺癌新靶标

2012-04-25 Beyond 生物谷

乳腺癌治疗的早期发现和进步能提高患者生存的机会,但是对抗这种疾病的新的治疗途径还需要我们进一步努力。发表在BioMed Central的Breast Cancer Research的杂志上的一项新的研究表明,蛋白PERP与细胞桥粒能抑制乳腺癌,这为今后乳腺癌的治疗提供了潜在的新的靶标。桥粒是相邻细胞间的一种斑点状黏着连接结构。 桥粒连接相邻细胞,这一微小蛋白质的集合调控身体内器官和组织的机械强度

乳腺癌治疗的早期发现和进步能提高患者生存的机会,但是对抗这种疾病的新的治疗途径还需要我们进一步努力。发表在BioMed Central的Breast Cancer Research的杂志上的一项新的研究表明,蛋白PERP与细胞桥粒能抑制乳腺癌,这为今后乳腺癌的治疗提供了潜在的新的靶标。桥粒是相邻细胞间的一种斑点状黏着连接结构。

桥粒连接相邻细胞,这一微小蛋白质的集合调控身体内器官和组织的机械强度。桥粒也被认为有助于抑制癌症。加州大学伯克利分校、斯坦福大学和加州大学戴维斯分校的研究人员发现蛋白PERP与桥粒一起存在于乳腺上皮细胞中。

该研究领导者Laura Attardi医生表示:该研究只要阐述了PERP的缺失是如何影响小鼠正常乳腺组织功能的。她说:PERP不足会造成乳腺上皮细胞桥粒蛋白表达的缺失,同时增强乳腺组织的炎症反应,肿瘤往往能更快熟发展。我们实验室研究也发现乳腺癌细胞有异常低水平的PERP表达。

这些结果表明PERP是一种细胞胶,能将细胞系在一起,但同时PERP在预防乳腺癌方面具有双重作用。炎性细胞促进癌症,缺乏细胞粘附是癌症转移的一大重要过程。PERP可能是监测乳腺癌的一个新的指标或治疗的新靶标。

doi:10.1186/bcr3171
PMC:
PMID:

Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer

Rachel L Dusek, Jamie L Bascom, Hannes Vogel, Sylvain Baron, Alexander D Borowsky, Mina J Bissell, Laura D Attardi.

Perp is a transcriptional target of both p53 during DNA damage-induced apoptosis and p63 during stratified epithelial development. Perp-/- mice exhibit postnatal lethality associated with severe blistering of the epidermis and oral mucosa, reflecting a critical role in desmosome-mediated intercellular adhesion in keratinocytes. However, Perp's role in tissue homeostasis in other p63-dependent stratified epithelial tissues is poorly understood. Given that p63 is essential for proper mammary gland development and that cell adhesion is fundamental for ensuring the proper architecture and function of the mammary epithelium, here we investigate Perp's function in the mammary gland.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725418, encodeId=dc101e25418e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 12 09:33:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710602, encodeId=a3561e10602af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jan 16 13:33:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351052, encodeId=ae7713510527e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352696, encodeId=b483135269678, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2013-01-12 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725418, encodeId=dc101e25418e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 12 09:33:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710602, encodeId=a3561e10602af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jan 16 13:33:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351052, encodeId=ae7713510527e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352696, encodeId=b483135269678, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725418, encodeId=dc101e25418e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 12 09:33:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710602, encodeId=a3561e10602af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jan 16 13:33:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351052, encodeId=ae7713510527e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352696, encodeId=b483135269678, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725418, encodeId=dc101e25418e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 12 09:33:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710602, encodeId=a3561e10602af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jan 16 13:33:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351052, encodeId=ae7713510527e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352696, encodeId=b483135269678, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 zhaojie88

相关资讯

EBCC-8:乳腺癌外科治疗进展荟萃

       作者:山东省肿瘤医院乳腺病中心 王永胜        作为两年一次的乳腺癌前沿性学术盛会,第8 届欧洲乳腺癌会议(EBCC-8)致力于呈现乳腺癌领域最新的进展、热点和理念。本次会议的目标包括:(1)关注临床研究向临床实践的快速转化;(2)鼓励乳腺癌各种治疗手段的整合和优化;(3)聚集患者代表、临床医

Nature:基因组和转录组学揭示乳腺癌的新的10个亚组分类法

4月18日,Nature杂志发表了乳腺癌的一张“新地图”,确认了10个不同的疾病亚型,是基于基因活性进行确认的,这张新地图将会彻底改变乳腺癌的诊断和治疗。该结果来自于全球最大的乳腺癌基因分析课题。 这项研究意义非凡,著名的乳腺癌专家Martine Piccart教授讲到,目前乳腺癌的分类分型过于简单,使得我们在选择病人的治疗上无法达到最优。我一点都不感到惊讶,乳腺癌不止4种分型,而至少有10种亚

NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌

       英国临床优化研究所(NICE)日前表示,将不会建议贝伐珠单抗联合卡培他滨治疗进展性转移性乳腺癌。在4月18日发布的新指南草案中,NICE指出,支持这种联合治疗的证据不足。目前已有2种含贝伐珠单抗的方案被欧盟批准作为进展性转移性乳腺癌的一线治疗,本次被NICE否定的方案是其中之一。        

2012 NCCN年会:NCCN肿瘤指南更新要点汇总

       肺癌指南 更新多        今年非小细胞肺癌指南更新颇多,包括对电视胸腔镜手术(VATS)、新药Crizotinib的推荐以及修订腺癌分期等。        分期推荐:EUS/EBUS及原位腺癌       &nb

乳腺癌筛查诊断和治疗进展

       作者:河北省乳腺疾病诊疗中心 河北医科大学第四医院乳腺中心 耿翠芝        化疗        70- 基因检测        荷兰癌症研究所 Linn报告的一项研究对427 例腋淋巴结转移阴性的患

管腔样细胞也能形成较大肿瘤

近期来自哥本哈根大学(CU)和美国劳伦斯伯克力国家实验室的研究人员的一个国际研究研究小组在乳腺癌研究中发现无干细胞特性的管腔样(Luminal-like)细胞也能形成较大的肿瘤,这一研究发现向当前普遍为人们所接受的理念:只有具有干细胞特性的基底样(basal-like)细胞才能形成侵袭性肿瘤提出了挑战。这一研究发现或有可能对于乳腺癌的诊断和治疗以及未来的个体化癌症用药产生重要的影响。相关研究成果发

Baidu
map
Baidu
map
Baidu
map